About the Company
Evofem Biosciences, Inc., is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EVFM News
Aditxt Announces Merger Agreement with Evofem Biosciences
Aditxt, Inc. has entered into a Merger Agreement with its subsidiary Adicure, Inc. and Evofem Biosciences, Inc., with subsequent amendments extending key dates relating to a joint proxy statement ...
Evofem Biosciences Inc EVFM
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Evofem Biosciences, Inc.: Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi ® (lactic acid, citric acid ...
Pearsanta acquires MDNA for $25M
The company moved into the women’s health market with the $100 million planned acquisition of Evofem Biosciences Inc., maker of the contraceptive gel Phexxi, which it reported on Dec. 12. The deals ...
Aditxt, Inc. (ADTX) stock price, news, quote & history – Yahoo Finance
Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for fiscal 2023, including record net sales of Phexxi® (lactic acid, citric acid, and potassium bitartrate) ...
Evofem Biosciences Announces Merger Agreement with Aditxt
Evofem Biosciences, Inc. has entered into a Merger Agreement with Aditxt, Inc. and its subsidiary, which has been amended twice, altering the timelines for a joint proxy statement and a Parent ...
Evofem Biosciences, Inc. (EVFM)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
About Evofem Biosciences Evofem Biosciences, Inc., (OTCQB: EVFM) is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA ...
EVFM Evofem Biosciences, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Evofem Biosciences Inc (EVFM)
Mersana Therapeutics, Inc. (NASDAQ:MRSN) exploded on Wednesday and had a big follow-through on Thursday, with a pop of 1.50, or 8.25%, to 19.69, after reaching a multi-week and ...
Evofem Biosciences, Inc. (EVFM)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...